These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 12483454)

  • 1. 'In vitro' binding of propofol to serum lipoproteins in thyroid dysfunction.
    de la Fuente L; Lukas JC; Vázquez JA; Jauregizar N; Calvo R; Suárez E
    Eur J Clin Pharmacol; 2002 Dec; 58(9):615-9. PubMed ID: 12483454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of unbound propofol concentrations in a diabetic population.
    de la Fuente L; Lukas JC; Jauregizar N; Vázquez JA; Calvo R; Suárez E
    Ther Drug Monit; 2002 Dec; 24(6):689-95. PubMed ID: 12451283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoprotein (a) levels in thyroid dysfunction before and after treatment.
    Sucić M; Bozikov V; Mesić R; Sokolić L
    Croat Med J; 1998 Mar; 39(1):19-22. PubMed ID: 9475802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered thyroid hormone binding to plasma lipoproteins in hypothyroidism.
    Benvenga S; Robbins J
    Thyroid; 1996 Dec; 6(6):595-600. PubMed ID: 9001194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered dose-to-effect of propofol due to pharmacokinetics in rats with experimental diabetes mellitus.
    Leal N; Calvo R; Agrad FZ; Lukas JC; de la Fuente L; Suarez E
    J Pharm Pharmacol; 2005 Mar; 57(3):317-25. PubMed ID: 15807987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The significance of lipoproteins in serum binding variations of propofol.
    Zamacona MK; Suárez E; García E; Aguirre C; Calvo R
    Anesth Analg; 1998 Nov; 87(5):1147-51. PubMed ID: 9806699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding of propofol to human serum albumin.
    Schywalsky M; Ihmsen H; Knoll R; Schwilden H
    Arzneimittelforschung; 2005; 55(6):303-6. PubMed ID: 16032968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Variation in high density lipoprotein cholesterol during treatment of thyroid gland diseases].
    Barbier R; Paffoy JC; Venard-Sassolas A; Berthezene F
    Diabete Metab; 1980 Sep; 6(3):213-7. PubMed ID: 7439494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Characterization of propofol binding to plasma proteins and possible interactions].
    Garrido MJ; Jiménez RM; Rodríguez-Sasiaín JM; Aguirre C; Aguilera L; Calvo R
    Rev Esp Anestesiol Reanim; 1994; 41(6):308-12. PubMed ID: 7838996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of plasma very low density lipoprotein, low density lipoprotein and high density lipoprotein on platelet aggregation in endogenous hypertriglyceridemia].
    Deng Z; Liu B; Zhou J; Zhang Z; Liu Y; Bai H
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Oct; 34(4):704-7. PubMed ID: 14619587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of intralipid on free propofol fraction assayed in human serum albumin solutions and human plasma.
    Kalitynski R; Dawidowicz AL; Poszytek J
    Acta Pharmacol Sin; 2006 Dec; 27(12):1637-41. PubMed ID: 17112420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in drug plasma concentrations of an extensively bound and highly extracted drug, propofol, in response to altered plasma binding.
    Hiraoka H; Yamamoto K; Okano N; Morita T; Goto F; Horiuchi R
    Clin Pharmacol Ther; 2004 Apr; 75(4):324-30. PubMed ID: 15060510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro release of propofol and binding capacity with regard to plasma constituents.
    Schicher M; Polsinger M; Hermetter A; Prassl R; Zimmer A
    Eur J Pharm Biopharm; 2008 Nov; 70(3):882-8. PubMed ID: 18640268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in lipoprotein research: biochemical and clinical aspects.
    Schettler G; Seidel D; Greten H
    Med J Aust; 1973 May; 1(19):942-6. PubMed ID: 4351788
    [No Abstract]   [Full Text] [Related]  

  • 15. Characteristics of serum protein binding of felodipine.
    Valle M; Esteban M; Rodríguez-Sasiaín JM; Calvo R; Aguirre C
    Res Commun Mol Pathol Pharmacol; 1996 Oct; 94(1):73-88. PubMed ID: 8948016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
    Erem C
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma lipoprotein alterations in thyroid dysfunction. Roles of lipoprotein lipase, hepatic lipase and LCAT.
    Valdemarsson S
    Acta Endocrinol Suppl (Copenh); 1983; 255():1-52. PubMed ID: 6575562
    [No Abstract]   [Full Text] [Related]  

  • 18. Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A.
    Superko HR; Berneis KK; Williams PT; Rizzo M; Wood PD
    Am J Cardiol; 2005 Nov; 96(9):1266-72. PubMed ID: 16253595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum lipoprotein and apolipoprotein concentrations in patients with hyperthyroidism and the effect of treatment with carbimazole.
    Boberg J; Dahlberg PA; Vessby B; Lithell H
    Acta Med Scand; 1984; 215(5):453-9. PubMed ID: 6588732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of unique lipoprotein subclasses for visceral obesity by component analysis of cholesterol profile in high-performance liquid chromatography.
    Okazaki M; Usui S; Ishigami M; Sakai N; Nakamura T; Matsuzawa Y; Yamashita S
    Arterioscler Thromb Vasc Biol; 2005 Mar; 25(3):578-84. PubMed ID: 15637308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.